Stemline Therapeutics Inc (NASDAQ:STML)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as $9.98 and last traded at $10.16, with a volume of 9799 shares changing hands. The stock had previously closed at $10.47.
Several brokerages have recently commented on STML. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. ValuEngine upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 16th. HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research report on Friday, August 10th. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Stemline Therapeutics in a research report on Monday, November 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.32.
The stock has a market cap of $323.41 million, a P/E ratio of -3.39 and a beta of 0.64.
Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.06). As a group, equities analysts forecast that Stemline Therapeutics Inc will post -2.8 earnings per share for the current fiscal year.
In related news, COO Kenneth Hoberman sold 26,296 shares of the stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $11.85, for a total transaction of $311,607.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 14.80% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. boosted its holdings in Stemline Therapeutics by 8.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 59,025 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 4,700 shares during the period. MetLife Investment Advisors LLC boosted its holdings in Stemline Therapeutics by 54.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock valued at $307,000 after acquiring an additional 6,527 shares during the period. Neuberger Berman Group LLC boosted its holdings in Stemline Therapeutics by 15.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 60,500 shares of the biopharmaceutical company’s stock valued at $1,004,000 after acquiring an additional 8,000 shares during the period. BlueMountain Capital Management LLC purchased a new stake in Stemline Therapeutics during the 2nd quarter valued at about $137,000. Finally, Bank of America Corp DE boosted its holdings in Stemline Therapeutics by 97.8% during the 2nd quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 10,159 shares during the period. Institutional investors own 64.20% of the company’s stock.
WARNING: This report was first published by Equities Focus and is the sole property of of Equities Focus. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.equitiesfocus.com/2018/12/08/stemline-therapeutics-stml-sets-new-12-month-low-at-9-98.html.
Stemline Therapeutics Company Profile (NASDAQ:STML)
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Recommended Story: What is insider trading?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.